TScan Therapeutics Inc
TCRX1.695USD
+0.075+4.63%
取引時間 （ET）15分遅れの株価
95.92M時価総額
損失額直近12ヶ月PER
詳細情報 TScan Therapeutics Inc 企業名
TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T), therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in clinical development for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. The Company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to build its ImmunoBank, a collection of solid tumor targets across different Human leukocyte antigens (HLAs) types in the TCR field. The Company is advancing approximately six solid tumor programs: TSC-204, TSC-200, TSC-203, TSC-201, TSC-202 and TSC-205.
企業情報
企業コードTCRX
会社名TScan Therapeutics Inc
上場日Jul 16, 2021
最高経営責任者「CEO」Mr. Gavin Macbeath, Ph.D.
従業員数194
証券種類Ordinary Share
決算期末Jul 16
本社所在地830 Winter Street
都市WALTHAM
証券取引所NASDAQ Global Market Consolidated
国United States of America
郵便番号02451
電話番号18573999500
ウェブサイトhttps://www.tscan.com
企業コードTCRX
上場日Jul 16, 2021
最高経営責任者「CEO」Mr. Gavin Macbeath, Ph.D.
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Zoran Zdraveski, J.D., Ph.D.
Dr. Zoran Zdraveski, J.D., Ph.D.
Chief Legal and Strategy Officer, Secretary
Chief Legal and Strategy Officer, Secretary
84.61K
+1694.13%
Mr. Gavin Macbeath, Ph.D.
Mr. Gavin Macbeath, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
49.77K
--
Mr. Garry A. Nicholson
Mr. Garry A. Nicholson
Independent Director
Independent Director
--
--
Mr. R. Keith Woods
Mr. R. Keith Woods
Independent Director
Independent Director
--
--
Dr. Stephen R. Biggar, M.D., Ph.D.
Dr. Stephen R. Biggar, M.D., Ph.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Jason A. Amello ,
Jason A. Amello ,
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Dr. Chrystal U. Louis
Dr. Chrystal U. Louis
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Katina Dorton
Ms. Katina Dorton
Independent Director
Independent Director
--
--
Dr. Barbara J. Klencke, M.D.
Dr. Barbara J. Klencke, M.D.
Independent Director
Independent Director
--
--
Dr. Gabriela Gruia, M.D.
Dr. Gabriela Gruia, M.D.
Independent Director
Independent Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Zoran Zdraveski, J.D., Ph.D.
Dr. Zoran Zdraveski, J.D., Ph.D.
Chief Legal and Strategy Officer, Secretary
Chief Legal and Strategy Officer, Secretary
84.61K
+1694.13%
Mr. Gavin Macbeath, Ph.D.
Mr. Gavin Macbeath, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
49.77K
--
Mr. Garry A. Nicholson
Mr. Garry A. Nicholson
Independent Director
Independent Director
--
--
Mr. R. Keith Woods
Mr. R. Keith Woods
Independent Director
Independent Director
--
--
Dr. Stephen R. Biggar, M.D., Ph.D.
Dr. Stephen R. Biggar, M.D., Ph.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Jason A. Amello ,
Jason A. Amello ,
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
収益内訳
FY2025Q1
FY2024
FY2023
FY2022
FY2021
データなし
地域別USD
会社名
収益
比率
United States
2.17M
0.00%
事業別
地域別
データなし
株主
更新時刻: Fri, May 16
更新時刻: Fri, May 16
株主統計
種類
株主統計
株主統計
比率
Lynx1 Capital Advisors LLC
15.19%
BVF Partners L.P.
9.35%
K2 HealthVentures LLC
6.89%
Adage Capital Management, L.P.
6.69%
Baker Bros. Advisors LP
5.32%
Other
56.56%
株主統計
株主統計
比率
Lynx1 Capital Advisors LLC
15.19%
BVF Partners L.P.
9.35%
K2 HealthVentures LLC
6.89%
Adage Capital Management, L.P.
6.69%
Baker Bros. Advisors LP
5.32%
Other
56.56%
種類
株主統計
比率
Investment Advisor
34.77%
Hedge Fund
23.77%
Venture Capital
19.29%
Investment Advisor/Hedge Fund
12.62%
Research Firm
2.10%
Individual Investor
0.39%
Bank and Trust
0.35%
Private Equity
0.09%
Pension Fund
0.02%
Other
6.59%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
191
48.87M
93.41%
-296.84K
2025Q1
198
46.53M
88.95%
-3.07M
2024Q4
184
47.92M
91.75%
+202.11K
2024Q3
172
45.30M
92.65%
-3.14M
2024Q2
147
48.79M
100.07%
+12.56M
2024Q1
110
39.09M
88.67%
+3.45M
2023Q4
95
36.63M
84.04%
+3.23M
2023Q3
84
33.69M
84.61%
-2.13M
2023Q2
78
32.77M
82.58%
-787.78K
2023Q1
72
14.05M
68.89%
-1.92M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Lynx1 Capital Advisors LLC
7.95M
15.19%
+2.59M
+48.32%
May 20, 2025
BVF Partners L.P.
4.89M
9.35%
+1.90M
+63.56%
Mar 31, 2025
K2 HealthVentures LLC
3.60M
6.89%
+2.90M
+414.67%
Dec 31, 2024
Adage Capital Management, L.P.
3.50M
6.69%
--
--
Mar 31, 2025
Baker Bros. Advisors LP
2.78M
5.32%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.61M
4.99%
-57.04K
-2.14%
Mar 31, 2025
The Vanguard Group, Inc.
2.36M
4.5%
-25.79K
-1.08%
Mar 31, 2025
Propel Bio Management, LLC
2.09M
3.99%
--
--
Mar 31, 2025
Pitango Venture Capital
2.08M
3.98%
+2.08M
--
Dec 31, 2023
Checkpoint Capital L.P.
2.02M
3.86%
+261.66K
+14.90%
Mar 31, 2025
詳細を見る
関連ETF
更新時刻: Sat, Aug 2
更新時刻: Sat, Aug 2
銘柄名
比率
Simplify Propel Opportunities ETF
2.25%
iShares Health Innovation Active ETF
0.08%
iShares Micro-Cap ETF
0.01%
ProShares Ultra Nasdaq Biotechnology
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
iShares Biotechnology ETF
0.01%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
DFA Dimensional US Core Equity Market ETF
0%
Proshares Ultra Russell 2000
0%
詳細を見る
Simplify Propel Opportunities ETF
比率2.25%
iShares Health Innovation Active ETF
比率0.08%
iShares Micro-Cap ETF
比率0.01%
ProShares Ultra Nasdaq Biotechnology
比率0.01%
Invesco Nasdaq Biotechnology ETF
比率0.01%
iShares Biotechnology ETF
比率0.01%
DFA Dimensional US Sustainability Core 1 ETF
比率0%
Dimensional US Core Equity 1 ETF
比率0%
DFA Dimensional US Core Equity Market ETF
比率0%
Proshares Ultra Russell 2000
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
